Stryker to buy Memometal Technologies for up to $162M

Kalamazoo, MI-based Stryker is buying privately held France's Memometal Technologies in an all-cash transaction for $150 million plus up to an additional $12 million of milestone payments. The transaction is expected to close in Q3.

Memometal makes products for extremity indications based on its proprietary methods for preparing and manufacturing a shape memory metal alloy. 

"The acquisition of Memometal provides Stryker with the platform to further establish our company as a key player in the rapidly growing foot and hand segment of the extremities market and creates a strong presence in the podiatric surgery market," said Stephen MacMillan, chairman, president and CEO of Stryker.

Stryker has been on a roll lately after announcing earlier this year that it might tap its cash stockpile to purchase assets after completing its purchase of Boston Scientific's neurovascular unit, showing its willingness to diversify.

Last month, Stryker announced it would buy all of the common stock of Orthovita, a specialty spine and orthopedic company, for $3.85 per share, representing a total value of roughly $316 million. The deal also includes $12 million in debt.

Stryker shares closed Friday at $60.20 and were inactive premarket, Dow Jones notes.

- see the Stryker statement
- get more from Dow Jones

Suggested Articles

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.

The former CEO of the molecular testing company Foundation Medicine, Troy Cox, has been named chairman of the Swiss big data firm Sophia Genetics.

Researchers at MIT used a machine-learning algorithm to uncover the potent antibiotic properties hiding within an old small-molecule candidate.